Cover Image
Market Research Report
Product code 
1039326

U.S. Clinical Trials Market Size, Share & Trend Analysis Report By Phase (Phase I, II, III, IV), Study Design (Interventional, Observational), By Indication (Oncology, Diabetes), And Segment Forecasts, 2021 - 2028

Published: | Grand View Research, Inc. | 120 Pages | Delivery time: 2-10 business days

Price

Back to Top
U.S. Clinical Trials Market Size, Share & Trend Analysis Report By Phase (Phase I, II, III, IV), Study Design (Interventional, Observational), By Indication (Oncology, Diabetes), And Segment Forecasts, 2021 - 2028
Published: November 30, 2021
Grand View Research, Inc.
Content info: 120 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

U.S. Clinical Trials Market Growth & Trends

The U.S. clinical trials market size is expected to reach USD 32.4 billion by 2028, registering a CAGR of 5.3% over the forecast period, according to a new report by Grand View Research, Inc. The shift towards personalized medicine, increasing R&D investments, and growing disease variation, as well as prevalence, are favoring the market growth. There has been a rise in the prevalence of diseases due to which, pharmaceutical companies are increasing their R&D expenditure to launch new therapeutics in the market. That has, in turn, increased the clinical trial value and complexity. Furthermore, the lower cost of clinical trials as a result of outsourcing services has strengthened clinical trial services in the U.S. As the number of people affected by the coronavirus has reached one million, the rapid spread of the virus around the globe is causing significant challenges to clinical trials and may forever change the way future trials are conducted.

The hospitals & clinics are less accessible, and it is unsafe and extremely difficult for patients enrolled in clinical trials to travel to sites. The current pandemic has placed a huge strain on the industry and is also likely to affect data analysis and interpretation. But that has also led to discoveries of conducting clinical trials effectively and efficiently. One such approach is to use Artificial Intelligence (AI) technology for clinical trials. Artificial intelligence uses software apps, data analytics, virtual monitoring, and online platforms to conduct every step of the clinical trial process, including patient recruitment, counseling, and consent. It helps in increasing precision and focuses on the efficiency of clinical trials. Thus, AI-generated technology has been gaining momentum as a healthcare offering, and the COVID-19 is adding more fuel to this initiative.

U.S. Clinical Trials Market Report Highlights

The phase III segment accounted for the largest revenue share in 2020. However, the phase I segment is estimated to register the fastest CAGR from 2021 to 2028

Patent expirations of blockbuster drugs and global financial crisis are factors expected to propel the market growth over the forecast period

The interventional design segment accounted for the largest share in 2020 and will expand further at a steady CAGR retaining the leading position over the forecast period

The oncology segment dominated the market in 2020 owing to the increasing number of cancer cases

The cardiovascular segment is also expected to witness significant growth over the forecasted period

Product Code: GVR-4-68039-580-4

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Phase
    • 1.1.2 Study Design
    • 1.1.3 Indication
    • 1.1.4 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.2 Volume Price Analysis (Model 2)
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1:
    • 1.10.2 Objective - 2:
    • 1.10.3 Objective - 3:
    • 1.10.4 Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 Clinical Trials Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis, by Stage for COVID-19
    • 3.3.1 Therapeutics in development: 271
    • 3.3.2 Vaccines in development: 106
  • 3.4 Fast track of clinical trials
    • 3.4.1 FDA initiative- CTAP
      • 3.4.1.1 Accelerating COVID-19 Therapeutic Interventions and Vaccines
  • 3.5 Solidarity clinical trial
    • 3.5.1 Participation in solidarity trials
    • 3.5.2 Solidarity clinical trial for vaccines
  • 3.6 Virtual clinical trials
    • 3.6.1 In-home clinical services:
  • 3.7 COVID-19 pandemic impact on clinical trial activity
    • 3.7.1 Disrupted clinical trials:
    • 3.7.2 Obstacles in clinical trials:
  • 3.8 Market Dynamics
    • 3.8.1 Market Driver Analysis
      • 3.8.1.1 Adoption of new technology in clinical research
      • 3.8.1.2 Shift towards personalized medicine
      • 3.8.1.3 Growing disease variation and prevalence
      • 3.8.1.4 Increasing collaboration in biomedical research
      • 3.8.1.5 Growth in CRO market
    • 3.8.2 Market Restraint Analysis
      • 3.8.2.1 Pricing pressure
    • 3.8.3 Industry Challenges
      • 3.8.3.1 Rising cost of clinical trial
  • 3.9 U.S. Clinical Trials Market Analysis Tools
    • 3.9.1 Porter's Five Forces Analysis
    • 3.9.2 PESTEL Analysis
    • 3.9.3 Major Deals & Strategic Alliances Analysis
      • 3.9.3.1 Collaboration
      • 3.9.3.2 Expansion
      • 3.9.3.3 Partnership
      • 3.9.3.4 Acquisition
      • 3.9.3.5 Product launch
      • 3.9.3.6 Merger
      • 3.9.3.7 Joint venture

Chapter 4 U.S. Clinical Trials Market: Phase Segment Analysis

  • 4.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
  • 4.2 Phase I
    • 4.2.1 Phase I market, 2016 - 2028 (USD Million)
  • 4.3 Phase II
    • 4.3.1 Phase II market, 2016 - 2028 (USD Million)
  • 4.4 Phase III
    • 4.4.1 Phase III market, 2016 - 2028 (USD Million)
  • 4.5 Phase IV
    • 4.5.1 Phase IV market, 2016 - 2028 (USD Million)

Chapter 5 U.S. Clinical Trials Market: Study Design Segment Analysis

  • 5.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
  • 5.2 Interventional Studies
    • 5.2.1 Interventional market, 2016 - 2028 (USD Million)
  • 5.3 Observational Studies
    • 5.3.1 Observational studies market, 2016 - 2028 (USD Million)
  • 5.4 Expanded Access Studies
    • 5.4.1 Expanded access studies market, 2016 - 2028 (USD Million)

Chapter 6 U.S. Clinical Trials Market: Indication Segment Analysis

  • 6.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
  • 6.2 Autoimmune/Inflammation
    • 6.2.1 Autoimmune/inflammation market, 2016 - 2028 (USD Million)
    • 6.2.2 Rheumatoid Arthritis
      • 6.2.2.1 Rheumatoid arthritis market, 2016 - 2028 (USD Million)
    • 6.2.3 Multiple Sclerosis (MS)
      • 6.2.3.1 Multiple sclerosis market, 2016 - 2028 (USD Million)
    • 6.2.4 Osteoarthritis
      • 6.2.4.1 Osteoarthritis market, 2016 - 2028 (USD Million)
    • 6.2.5 Irritable Bowel Syndrome (IBS)
      • 6.2.5.1 Irritable Bowel Syndrome (IBS) market, 2016 - 2028 (USD Million)
    • 6.2.6 Others
      • 6.2.6.1 Others market, 2016 - 2028 (USD Million)
  • 6.3 Pain Management
    • 6.3.1 Pain management market, 2016 - 2028 (USD Million)
    • 6.3.2 Chronic pain
      • 6.3.2.1 Chronic pain market, 2016 - 2028 (USD Million)
    • 6.3.3 Acute pain
      • 6.3.3.1 Acute pain market, 2016 - 2028 (USD Million)
  • 6.4 Oncology
    • 6.4.1 Oncology market, 2016 - 2028 (USD Million)
    • 6.4.2 Blood cancer
      • 6.4.2.1 Blood cancer market, 2016 - 2028 (USD Million)
    • 6.4.3 Solid tumors
      • 6.4.3.1 Solid tumors market, 2016 - 2028 (USD Million)
    • 6.4.4 Others
      • 6.4.4.1 Others market, 2016 - 2028 (USD Million)
  • 6.5 CNS Conditions
    • 6.5.1 CNS conditions market, 2016 - 2028 (USD Million)
    • 6.5.2 Epilepsy
      • 6.5.2.1 Epilepsy market, 2016 - 2028 (USD Million)
    • 6.5.3 Parkinson's disease (PD)
      • 6.5.3.1 Parkinson's disease (PD) market, 2016 - 2028 (USD Million)
    • 6.5.4 Huntington's disease
      • 6.5.4.1 Huntington's disease market, 2016 - 2028 (USD Million)
    • 6.5.5 Stroke
      • 6.5.5.1 Stroke market, 2016 - 2028 (USD Million)
    • 6.5.6 Traumatic Brain Injury (TBI)
      • 6.5.6.1 Traumatic Brain Injury (TBI) market, 2016 - 2028 (USD Million)
    • 6.5.7 Amyotrophic Lateral Sclerosis (ALS)
      • 6.5.7.1 Amyotrophic Lateral Sclerosis (ALS) market, 2016 - 2028 (USD Million)
    • 6.5.8 Muscle Regeneration
      • 6.5.8.1 Muscle Regeneration market, 2016 - 2028 (USD Million)
    • 6.5.9 Others
      • 6.5.9.1 Others market, 2016 - 2028 (USD Million)
  • 6.6 Diabetes
    • 6.6.1 Diabetes market, 2016 - 2028 (USD Million)
  • 6.7 Obesity
    • 6.7.1 Obesity market, 2016 - 2028 (USD Million)
  • 6.8 Cardiovascular
    • 6.8.1 Cardiovascular market, 2016 - 2028 (USD Million)
  • 6.9 Other Indications
    • 6.9.1 Other indications market, 2016 - 2028 (USD Million)

Chapter 7 U.S. Clinical Trials Indication Outlook, by Study Design, Criss-Cross Analysis

  • 7.1 U.S. autoimmune/inflammation clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.1.1 Interventional studies
      • 7.1.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.1.2 Observational Studies
      • 7.1.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.1.3 Expanded access
      • 7.1.3.1 Expanded access market, 2016 - 2028 (USD Million)
  • 7.2 U.S. pain management clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.2.1 Interventional studies
      • 7.2.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.2.2 Observational studies
      • 7.2.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.2.3 Expanded access
      • 7.2.3.1 Expanded access market, 2016 - 2028 (USD Million)
  • 7.3 U.S. oncology clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.3.1 Interventional studies
      • 7.3.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.3.2 Observational studies
      • 7.3.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.3.3 Expanded access
      • 7.3.3.1 Expanded access market, 2016 - 2028 (USD Million)
  • 7.4 U.S. CNS condition clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.4.1 Interventional studies
      • 7.4.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.4.2 Observational studies
      • 7.4.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.4.3 Expanded access
      • 7.4.3.1 Expanded access market, 2016 - 2028 (USD Million)
  • 7.5 U.S. diabetes clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.5.1 Interventional studies
      • 7.5.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.5.2 Observational studies
      • 7.5.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.5.3 Expanded access
      • 7.5.3.1 Expanded access market, 2016 - 2028 (USD Million)
  • 7.6 U.S. obesity clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.6.1 Interventional studies
      • 7.6.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.6.2 Observational studies
      • 7.6.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.6.3 Expanded access
      • 7.6.3.1 Expanded access market, 2016 - 2028 (USD Million)
  • 7.7 U.S. cardiovascular clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.7.1 Interventional studies
      • 7.7.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.7.2 Observational Studies
      • 7.7.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.7.3 Expanded access
      • 7.7.3.1 Expanded access market, 2016 - 2028 (USD Million)
  • 7.8 U.S. others clinical trials market, by study design, 2016 - 2028 (USD Million)
    • 7.8.1 Interventional studies
      • 7.8.1.1 Interventional studies market, 2016 - 2028 (USD Million)
    • 7.8.2 Observational Studies
      • 7.8.2.1 Observational studies market, 2016 - 2028 (USD Million)
    • 7.8.3 Expanded access
      • 7.8.3.1 Expanded access market, 2016 - 2028 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Company Profiles
    • 8.1.1 IQVIA Holdings Inc.
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Service benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 PAREXEL International Corporation
      • 8.1.2.1 Company overview
      • 8.1.2.2 Service benchmarking
      • 8.1.2.3 Strategic initiatives
    • 8.1.3 Pharmaceutical Product Development (PPD)
      • 8.1.3.1 Company overview
      • 8.1.3.2 Service benchmarking
      • 8.1.3.3 Strategic initiatives
    • 8.1.4 Charles River Laboratory
      • 8.1.4.1 Company overview
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Service benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 ICON plc
      • 8.1.5.1 Company overview
      • 8.1.5.2 Financial performance
      • 8.1.5.3 Service benchmarking
      • 8.1.5.4 Strategic initiatives
    • 8.1.6 PRA Health Sciences
      • 8.1.6.1 Company overview
      • 8.1.6.2 Financial performance
      • 8.1.6.3 Service benchmarking
      • 8.1.6.4 Strategic initiatives
    • 8.1.7 Syneos Health Inc.
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Service benchmarking
      • 8.1.7.4 Strategic initiatives
    • 8.1.8 SGS SA
      • 8.1.8.1 Company overview
      • 8.1.8.2 Financial performance
      • 8.1.8.3 Service benchmarking
      • 8.1.8.4 Strategic initiatives
    • 8.1.9 Wuxi AppTec
      • 8.1.9.1 Company overview
      • 8.1.9.2 Financial performance
      • 8.1.9.3 Service benchmarking
      • 8.1.9.4 Strategic initiatives
    • 8.1.10 Eli Lilly and Company
      • 8.1.10.1 Company overview
      • 8.1.10.2 Financial performance
      • 8.1.10.3 Service benchmarking
    • 8.1.11 Novo Nordisk A/S
      • 8.1.11.1 Company overview
      • 8.1.11.2 Financial performance
      • 8.1.11.3 Service benchmarking
    • 8.1.12 Pfizer Inc.
      • 8.1.12.1 Company overview
      • 8.1.12.2 Financial performance
      • 8.1.12.3 Service benchmarking
      • 8.1.12.4 Strategic initiatives
    • 8.1.13 Covance Inc.
      • 8.1.13.1 Company overview
      • 8.1.13.2 Financial performance
      • 8.1.13.3 Service benchmarking
      • 8.1.13.4 Strategic initiatives
    • 8.1.14 Clinipace
      • 8.1.14.1 Company overview
      • 8.1.14.2 Service benchmarking

List of Tables

  • Table 1 U.S. clinical trials market, by phase, 2016 - 2028 (USD Million)
  • Table 2 U.S. clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 3 U.S. clinical trials market, by indication, 2016 - 2028 (USD Million)
  • Table 4 U.S. autoimmune/inflammation clinical trials market, by indication, 2016 - 2028 (USD Million)
  • Table 5 U.S. pain management clinical trials market, by indication, 2016 - 2028 (USD Million)
  • Table 6 U.S. oncology clinical trials market, by indication, 2016 - 2028 (USD Million)
  • Table 7 U.S. CNS conditions clinical trials market, by indication, 2016 - 2028 (USD Million)
  • Table 8 U.S. autoimmune/inflammation clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 9 U.S. pain management clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 10 U.S. oncology clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 11 U.S. CNS condition clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 12 U.S. diabetes clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 13 U.S. obesity clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 14 U.S. cardiovascular clinical trials market, by study design, 2016 - 2028 (USD Million)
  • Table 15 U.S. others clinical trials market, by study design, 2016 - 2028 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 U.S. Clinical trials market snapshot (2020)
  • Fig. 10 U.S. clinical trials market segmentation
  • Fig. 11 U.S. clinical trials market: Strategy framework
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Virtual clinical trials
  • Fig. 16 Companies with affected trials, by size
  • Fig. 17 Affected trials, by study phase
  • Fig. 18 Market driver relevance analysis (Current & future impact)
  • Fig. 19 Market restraint relevance analysis (Current & future impact)
  • Fig. 20 Porter's five forces analysis
  • Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 22 U.S. clinical trials market phase outlook: Segment dashboard
  • Fig. 23 U.S. clinical trials market: Phase movement analysis
  • Fig. 24 Phase I market, 2016 - 2028 (USD Million)
  • Fig. 25 Phase II market, 2016 - 2028 (USD Million)
  • Fig. 26 Phase III market, 2016 - 2028 (USD Million)
  • Fig. 27 Phase IV market, 2016 - 2028 (USD Million)
  • Fig. 28 U.S. clinical trials market study design outlook: Segment dashboard
  • Fig. 29 U.S. clinical trials market: Study design movement analysis
  • Fig. 30 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 31 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 32 Expanded access studies market, 2016 - 2028 (USD Million)
  • Fig. 33 U.S. clinical trials market indication outlook: Segment dashboard
  • Fig. 34 U.S. clinical trials market: Indication movement analysis
  • Fig. 35 Autoimmune/inflammation market, 2016 - 2028 (USD Million)
  • Fig. 36 Rheumatoid arthritis clinical trial by phase (%)
  • Fig. 37 Rheumatoid arthritis market, 2016 - 2028 (USD Million)
  • Fig. 38 Multiple sclerosis clinical trial by phase (%)
  • Fig. 39 Multiple sclerosis market, 2016 - 2028 (USD Million)
  • Fig. 40 Osteoarthritis clinical trials by phase (%)
  • Fig. 41 Osteoarthritis market, 2016 - 2028 (USD Million)
  • Fig. 42 Irritable bowel syndrome clinical trials by phase (%)
  • Fig. 43 Irritable Bowel Syndrome (IBS) market, 2016 - 2028 (USD Million)
  • Fig. 44 Others market, 2016 - 2028 (USD Million)
  • Fig. 45 Pain management market, 2016 - 2028 (USD Million)
  • Fig. 46 Chronic pain clinical trial by phase (%)
  • Fig. 47 Chronic pain market, 2016 - 2028 (USD Million)
  • Fig. 48 Acute pain clinical trial by phase (%)
  • Fig. 49 Acute pain market, 2016 - 2028 (USD Million)
  • Fig. 50 Oncology market, 2016 - 2028 (USD Million)
  • Fig. 51 Blood cancer market, 2016 - 2028 (USD Million)
  • Fig. 52 Solid tumors market, 2016 - 2028 (USD Million)
  • Fig. 53 Others market, 2016 - 2028 (USD Million)
  • Fig. 54 CNS conditions market, 2016 - 2028 (USD Million)
  • Fig. 55 Epilepsy market, 2016 - 2028 (USD Million)
  • Fig. 56 Parkinson's disease (PD) market, 2016 - 2028 (USD Million)
  • Fig. 57 Huntington's disease market, 2016 - 2028 (USD Million)
  • Fig. 58 Stroke market, 2016 - 2028 (USD Million)
  • Fig. 59 Traumatic Brain Injury (TBI) market, 2016 - 2028 (USD Million)
  • Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2016 - 2028 (USD Million)
  • Fig. 61 Muscle regeneration market, 2016 - 2028 (USD Million
  • Fig. 62 Others market, 2016 - 2028 (USD Million)
  • Fig. 63 Diabetes market, 2016 - 2028 (USD Million)
  • Fig. 64 Obesity clinical trial by phase (%)
  • Fig. 65 Obesity market, 2016 - 2028 (USD Million)
  • Fig. 66 Cardiovascular market, 2016 - 2028 (USD Million)
  • Fig. 67 Others indications market, 2016 - 2028 (USD Million)
  • Fig. 68 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 69 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 70 Expanded access market, 2016 - 2028 (USD Million)
  • Fig. 71 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 72 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 73 Expanded access market, 2016 - 2028 (USD Million)
  • Fig. 74 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 75 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 76 Expanded access market, 2016 - 2028 (USD Million)
  • Fig. 77 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 78 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 79 Expanded access market, 2016 - 2028 (USD Million)
  • Fig. 80 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 81 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 82 Expanded access market, 2016 - 2028 (USD Million)
  • Fig. 83 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 84 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 85 Expanded access market, 2016 - 2028 (USD Million)
  • Fig. 86 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 87 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 88 Expanded access market, 2016 - 2028 (USD Million)
  • Fig. 89 Interventional studies market, 2016 - 2028 (USD Million)
  • Fig. 90 Observational studies market, 2016 - 2028 (USD Million)
  • Fig. 91 Expanded access market, 2016 - 2028 (USD Million)